Good question. I think we'd be in a lot of pain if they pulled...

Good question. I think we'd be in a lot of pain if they pulled guidance completely or revised it down. We'd be stuck in a lower share price range and our NNZ-2591 progress won't help move the SP much. If NNZ-2591 goes well, we'd get a similar back ended re-rate, but many investors wouldn't want to wait around that long (to phase 3 for PMS) so the SP would probably suffer in the short-medium term.

So far (outside of the share price) everything Neuren and Acadia has publicly announced has been positive to at least meeting guidance. I think being on track to meeting guidance (even if on the lower end) will be considered a decent result given where the SP's are for NEU and ACAD.